Labiana Returns to the MedCap Forum to Present Its Business Model and Expansion Plan to Investors
- Las reuniones one- to-one tendrán lugar el día 27 de mayo en la Bolsa de Madrid y se centrarán en compartir el nuevo equity story de la compañía y su plan estratégico de crecimiento
- A estos encuentros con inversores asistirán Manuel Ramos, Presidente y CEO; Sandra Villagrasa, Directora General, John William Nellis, miembro del Consejo de Administración, y Cristina Ramos, Directora de Relación con Inversores y de Comunicación Corporativa
Madrid, May 26, 2025 – Labiana, the pharmaceutical company specializing in both animal and human health and listed on BME Growth, returns this year to the MedCap Forum—the key event for European small and mid-cap investors listed in Spain—to present its business model and expansion plan to interested investors.
The 21st edition of this flagship financial sector event will take place from May 27 to 29 at the Madrid Stock Exchange Palace. After formally introducing itself to investors at last year’s forum, Labiana will participate on May 27 to hold private one-to-one meetings, offering a comprehensive overview of the company’s new equity story.
During these meetings, Manuel Ramos (Chairman and CEO), Sandra Villagrasa (General Manager), John William Nellis (Board Member), and Cristina Ramos (Head of Investor Relations and Corporate Communications) will address key topics such as growth opportunities in the animal and human health sectors, an expanding portfolio of proprietary and third-party products, the company’s 2024 results, and its new strategic plan currently underway.
Just weeks ago, Labiana publicly announced its 2024 financial results, highlighting a 13.3% increase in revenue, reaching €66.26 million. Both the animal and human health divisions saw double-digit growth, with revenue rising 10.6% and 16% respectively. In addition, the company—the top-performing stock on BME Growth in 2024 with a 136.8% increase in value—tripled its EBITDA to €9.43 million and posted an EBIT of €4.96 million.
According to Manuel Ramos, Chief Commercial Officer of Labiana Life, “Events like this strengthen our commitment to visibility and transparency with current and potential investors, while also helping to boost interest in BME Growth-listed companies. Moreover, we are entering a key moment for the expansion of our business, as shown by our 2024 results and the recent entry of investor Héctor Ara into our capital structure.”
About Labiana
Labiana Health is an independent, integrated international leader in animal and human health, with a diversified portfolio of products and businesses and a broad client base of top-tier companies with long-lasting relationships built on trust. It has subsidiaries in Spain, Serbia, Turkey, and Mexico, with production centers distributed between Spain and Serbia. Labiana’s products are present in over 150 markets, with product registrations in more than 90 countries. The group has two differentiated and complementary business lines: contract manufacturing in both veterinary and human health, which provides stability and income visibility, and the development, manufacturing, and commercialization of its own products in both animal and human health, driving growth. The company debuted on BME Growth in June 2022, becoming the first veterinary company to list on Spain’s BME Growth Market.
FORWARD-LOOKING STATEMENTS
This communication may contain information and forward-looking statements or declarations regarding LABIANA. It may also include financial projections and/or estimates with their underlying assumptions, statements concerning plans, objectives, and expectations regarding future operations, investments, synergies, products, and services, as well as statements about future results. Forward-looking statements are not historical facts and are generally identified by the use of terms such as “expects,” “anticipates,” “believes,” “intends,” “estimates,” and similar expressions.
While LABIANA believes that the expectations reflected in such statements are reasonable, investors and shareholders of LABIANA are cautioned that forward-looking information and statements are subject to risks and uncertainties, many of which are difficult to predict and are generally beyond the control of LABIANA. These factors could cause actual results and developments to differ significantly from those expressed, implied, or projected in the forward-looking information and statements.
Such risks and uncertainties include those identified in documents submitted by LABIANA to BME Growth, which are publicly accessible. It is recommended not to make decisions based on forward-looking statements, as they refer solely to the date on which they were made, do not constitute a guarantee of future results, and have not been audited by LABIANA’s auditors.
All forward-looking statements or declarations, whether oral or written, made by LABIANA or any of its board members, executives, employees, or representatives are expressly subject to these warnings. The forward-looking statements or declarations included in this document are based on the information available to LABIANA as of the date of this communication.
Leave a Comment